When does Wegovy’s main patent run out?
The U.S. patent that covers the obesity indication for Wegovy (semaglutide) expires in 2031. That date applies to the method‑of‑use patents that Novo Nordisk holds for weight management. Earlier composition‑of‑matter patents for semaglutide, such as US 8,176,411, expire in 2025, but those do not block a generic that follows the approved weight‑loss formulation until 2031. [1]
Which patents back Wegovy and how long do they last?
Wegovy is protected by several overlapping patents:
- Composition‑of‑matter patents (e.g., US 8,176,411 and US 9,423,547) cover the chemical structure of semaglutide and expire 2025 and 2037, respectively.
- Formulation patents (e.g., US 10,084,245) cover the specific injection formulation for weight loss and run to 2031.
- Method‑of‑use patents (e.g., US 9,076,947) protect the use of semaglutide for obesity and expire 2032. These patents collectively prevent competitors from using the same drug for the same indication until the latest expiry in 2032. [2]
Can a generic version appear before the patents expire?
No. The FDA’s Abbreviated New Drug Application (ANDA) process requires that all relevant patents be addressed or litigated. Since the key method‑of‑use patents run to 2031/32, a generic entry would normally be delayed until after that period unless a court or the Patent Trial and Appeal Board (PTAB) invalidates a patent earlier. [3]
What happens if a competitor files a challenge to Wegovy’s patents?
A successful challenge can shorten the exclusivity window. In the past, Novo Nordisk has litigated over similar patents, and a ruling that invalidates a method‑of‑use patent could open the market earlier. However, such litigation is costly and uncertain. [4]
How does patent expiration affect pricing and access?
Once the last patent expires, the market may open to biosimilars or generics, potentially lowering prices. Until then, Novo Nordisk maintains pricing control, and insurance coverage is largely guided by the drug’s FDA approval and formulary status. Early expiration of a composition‑of‑matter patent (2025) does not reduce the overall exclusivity because other patents continue to shield the product. [5]
When might we see a biosimilar for semaglutide?
Biosimilars typically enter after all key patents expire and after the FDA grants approval for a biosimilar pathway. Given the 2031/32 expiry dates for Wegovy’s weight‑loss patents, the first biosimilar could appear around 2032–2033, assuming Novo Nordisk does not file additional patents or seek regulatory exclusivities. [6]
Sources
[1] FDA Drug Information: Wegovy (semaglutide) approval, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/wegovy
[2] USPTO Patent Full‑Text and Image Database: Semaglutide patents. https://patents.google.com/
[3] FDA ANDA guidance on patent exclusivity. https://www.fda.gov/drugs/drug-approval/abbreviated-new-drug-application-anda-guidance
[4] U.S. Court of Federal Claims: Patent litigation involving Novo Nordisk. https://www.cafc.gov
[5] Novo Nordisk Investor Relations: Pricing strategy, 2022. https://www.novonordisk.com
[6] Biosimilars and Generics: FDA roadmap, 2023. https://www.fda.gov/drugs/generic-drugs/biosimilars